Eli Lilly and Company announced results from its Phase 3 BRUIN CLL-322 trial, demonstrating that adding Jaypirca to a venetoclax time-limited regimen cuts the risk of disease progression or death by 45% in previously treated CLL/SLL patients.
Johnson & Johnson announced positive Phase 3 MonumenTAL-3 trial data demonstrating that a TALVEY-based bispecific combination significantly reduces the risk of progression or death in earlier-line relapsed or refractory multiple myeloma.
AstraZeneca is advancing its investigational once-daily oral small-molecule GLP-1 receptor agonist, elecoglipron, into a broad Phase III programme after Phase IIb trials demonstrated up to 11.8% weight loss and a 1.9% reduction in HbA1c.
At the ADA 2026 Scientific Sessions, Novo Nordisk unveiled Phase 2 data for zenagamtide (amycretin), demonstrating exceptional blood sugar control and weight loss in type 2 diabetes.
Johnson & Johnson has shared late-breaking results from its Phase 2 JASMINE trial highlighting that nipocalimab achieves a sustained reduction in systemic lupus erythematosus (SLE) disease activity through 52 weeks.
The Phase III SERENA-6 trial reveals that switching to AstraZeneca Camizestrant Breast Cancer Treatment yields a 55% reduction in disease progression risk for advanced HR-positive breast cancer patients with emergent ESR1 mutations.
Roche announces groundbreaking Phase II data for enicepatide and petrelintide ahead of the ADA 2026 Scientific Sessions, positioning its pipeline for best-in-class weight loss and advanced combination therapies.
Novartis announced impressive 144-week data for its groundbreaking STAMP inhibitor, showcasing widening superior molecular response rates and better tolerability compared to standard TKIs in newly diagnosed CML patients.
Pfizer’s Phase 3 TALAPRO-3 trial reveals that combining Talzenna with Xtandi significantly improves radiographic progression-free survival by more than 50% in HRR gene-mutated mCSPC patients.
Updated data from the CHRYSALIS-2 study reveals that Johnson & Johnson’s RYBREVANT® plus LAZCLUZE® combination achieves a historic median overall survival of 41.0 months as a first-line therapy for atypical EGFR-mutated advanced non-small cell lung cancer.
